We report herein that incremental dosing of gliclazide MR 60 mg QD over 6 months was well tolerated and led to significant and clinically meaningful HbA1c reductions, as early as 3 months, in individuals with type 2 diabetes, not treated with insulin and with a broad range of baseline HbA1c. This evidence concerns the gene INS and type 2 diabetes mellitus.